Hinova Pharmaceuticals Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	20.67	-	-	-	-
Other Revenue	-	0.37	-	1.65	-
Revenue	20.67	0.37	-	1.65	-
Revenue Growth (YoY)	5535.71%	-	-	-	-
Cost of Revenue	-	0.34	-	0.77	-
Gross Profit	20.67	0.03	-	0.88	-
Selling, General & Admin	-	53.49	88	97.04	80.28
Research & Development	-	174.03	248.27	251.37	264.93
Other Operating Expenses	156.47	0.41	0.42	0.35	0.06
Operating Expenses	156.47	227.94	336.69	348.75	345.27
Operating Income	-135.79	-227.91	-336.69	-347.87	-345.27
Interest Expense	-	-0.53	-1.49	-3.92	-2.56
Interest & Investment Income	-	19.16	28.62	22.5	26.97
Currency Exchange Gain (Loss)	-	1.35	1.4	7.56	-2.1
Other Non Operating Income (Expenses)	-0.89	-0.43	-0.38	-0.17	-0.14
EBT Excluding Unusual Items	-136.68	-208.35	-308.53	-321.9	-323.11
Gain (Loss) on Sale of Investments	-	3.96	8.35	10.27	-1.5
Gain (Loss) on Sale of Assets	-	-0	-0.01	-0	-0
Other Unusual Items	-	4.91	6.04	10.12	18.44
Pretax Income	-136.68	-199.48	-294.14	-301.51	-306.18
Income Tax Expense	0	0.01	0.02	-	-
Earnings From Continuing Operations	-136.69	-199.5	-294.16	-301.51	-306.18
Net Income	-136.69	-199.5	-294.16	-301.51	-306.18
Net Income to Common	-136.69	-199.5	-294.16	-301.51	-306.18
Shares Outstanding (Basic)	99	99	99	91	74
Shares Outstanding (Diluted)	99	99	99	91	74
Shares Change (YoY)	-0.20%	0.21%	9.06%	22.21%	5.74%
EPS (Basic)	-1.38	-2.01	-2.97	-3.32	-4.12
EPS (Diluted)	-1.38	-2.01	-2.97	-3.32	-4.12
Free Cash Flow	-	-276.63	-354.68	-384.13	-247.6
Free Cash Flow Per Share	-	-2.79	-3.58	-4.23	-3.33
Gross Margin	100.00%	8.43%	-	53.57%	-
Operating Margin	-656.84%	-62127.45%	-	-21072.49%	-
Profit Margin	-661.16%	-54382.81%	-	-18264.53%	-
Free Cash Flow Margin	-	-75410.46%	-	-23269.07%	-
EBITDA	-133.72	-225.83	-334.4	-345.96	-342.22
D&A For EBITDA	2.07	2.07	2.28	1.91	3.05
EBIT	-135.79	-227.91	-336.69	-347.87	-345.27
Revenue as Reported	-	0.37	-	1.65	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.